Responsible for the manufacture of drug substance for early and late stage clinical trials. Responsible for the operation of the Gaithersburg Pilot Facility comprising production trains from 200L to 2000L scale. Accountable for all manufacturing activities including cell banking, buffer and media preparation, inoculum preparation, cell culture, purification, and bulk filling. Accountable for the adherence to CGMP and compliance with site procedures

Boca Raton, Florida, December 4, 2007 – Biotest Pharmaceuticals Corporation, a leading developer of immunology biotherapeutic products, today announced that it has completed the acquisition of the Nabi Biopharmaceuticals (Nasdaq: NABI) Biologics business unit for $185 million in cash. Biotest Pharmaceuticals is a wholly-owned subsidiary of Biotest AG, which announced the acquisition of the Nabi Biologics product pipeline (including Nabi-HB®), a state-of-the-art plasma protein production plant, the Boca Raton headquarters and nine FDA- and European-certified plasma collection centers across the U.S. in September 2007. This acquisition also includes certain assets in Nabi’s Corporate Shared Services group.